NASDAQ · PLRX

Pliant Therapeutics, Inc.

$1.08 -$0.01 (-0.92%) 1D Market open

Key Metrics

$67.49M
Market cap
P/E · TTM
$0
Revenue · TTM
−$113.22M
Net income
EPS · TTM $-1.85
Dividend yield
Free cash flow −$98.81M
Beta · 1Y 0.89
EBITDA · TTM −$117.70M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 18
    The stock moved +10.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 18

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$67.49M
Enterprise value−$103.40M
Shares outstanding61.9M
52-wk range$1.05 – $1.95
Avg volume · 20D682.8K
Net cash $170.89M
Book value / share$2.70
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Pliant Therapeutics, Inc.
IPO dateJun 3, 2020
Employees49

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -48.3% · —

Financial Health

Current ratio16.89
Quick ratio
Debt / equity0.00
Debt / EBITDA 0.00Low leverage
Net cash $170.89M
Working capital$164.57M

Cash Flow · TTM

Operating CF −$98.70M
Capex −$112.00K
Free cash flow −$98.81M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-6.0
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings